Peptide Sciences, the largest US gray-market peptide vendor, shut down in March 2026 amid 50+ FDA warning letters and DOJ pleas. In July an FDA committee voted to allow compounding of BPC-157, TB-500 and four others, but as of October 2026 FDA has not listed them, so buyers face a shrinking gray market and no legal pharmacy route yet.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
What happened to Peptide Sciences?
It voluntarily shut down on March 6, 2026, ahead of expected FDA enforcement. It was by most estimates the largest US gray-market research-peptide vendor, with roughly $7.4M in December 2025 sales, and its closure was the most visible event in a 12-month wave of warning letters and DOJ criminal pleas.
Where can people get these peptides now?
Not yet from a US compounding pharmacy legally: as of October 2026 none of the six committee-backed peptides is on the 503A list. Supply has shifted to remaining "research use only" sellers and to telehealth platforms; a temporary-access policy has been reported but not published.1
What did the PCAC committee decide in July 2026?
It recommended six of seven reviewed peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, rejecting only Emideltide/DSIP. All votes overrode FDA career-staff recommendations against inclusion. The votes are advisory; FDA's final determination is pending.1
What is the catch with compounded peptides?
A peer-reviewed analysis documented the safety-standards gap: without an approved USP monograph, the full analytical burden for identity, purity, impurity profiling and counter-ion form falls on the compounder, a structurally harder bar than previous bulk nominations.1
What would change this picture?
FDA's final rule on the six recommended peptides (accept all or split), possibly a USP monograph requirement, and the February 2027 follow-up PCAC for five more peptides: GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF.1
02What this means for you (as of 15 October 2026)
If you bought peptides from "research use only" sites, the biggest US supplier is gone and FDA has spent a year sending warning letters to the rest. The legal alternative, a prescription filled by a 503A compounding pharmacy, is not open yet for BPC-157, TB-500, KPV, MOTS-c, Semax or Epitalon: the July 2026 committee vote in their favour was advisory, and as of 9 October none is on the 503A list or in FDA's Category 1 (MDside). In practice, buyers are left between a shrinking gray market and a legal channel that doesn't exist yet.
- "Research use only" is not a legal shield for the seller, and it tells you nothing about what is in the vial. FDA staff's central objection to these peptides is identity and purity (FDA briefing).
- Telehealth and clinic channels advertising these peptides depend on pharmacies with no listed bulk substance to work from; it is fair to ask them which legal pathway they use.
- If a temporary-access policy appears (reported by the Washington Post on 7 Oct 2026, not yet published), it would be FDA declining to enforce under conditions, not approval, and state pharmacy boards would still apply their own rules (MDside).
03Criticisms of the crackdown
- It removed supply, not demand. A pharmacist representing peptide makers told NPR the restrictions "opened up a gray and black market"; the compounding trade group has asked FDA for interim, patient-specific compounding with cGMP-sourced ingredients and adverse-event reporting (MDside).
- Weak harm signal. FDA's BPC-157 file lists three adverse-event reports after injection, with attribution described as unclear (FDA briefing).
04Criticisms of opening it up
- Quality burden moves to the pharmacy. With no USP monograph, each compounder must prove identity, purity, impurity profile and salt form on its own, a harder bar than earlier bulk nominations (Willis & Vu 2026, PMID 42752426).
- Human evidence is still thin. The newest papers are preclinical, e.g. a critical review of rodent ischemia-reperfusion data for BPC-157 (PMID 42794771) and a rat Achilles-tendon comparison of BPC-157 and TB-500 (PMID 42542926).
05Background
Peptide Sciences — by most estimates the largest gray-market research-peptide vendor in the US (~$7.4M Dec 2025 sales) — voluntarily shut down ahead of expected FDA enforcement. This is the most visible event in a 12-month enforcement wave that has produced 50+ warning letters, DOJ criminal guilty pleas, and massive patient migration to compounding pharmacies and telehealth platforms.
As of April 2026, FDA removed 12 peptides from Category 2 (significant safety concerns) following withdrawal of nominations, shifting them to formal PCAC review for potential 503A Bulks List inclusion. GHK-Cu was removed from Category 1.
As of October 3, 2026, FDA has not yet issued a final rule on the PCAC-recommended 503A Bulks List additions. The peer-reviewed pharmacy-compounding literature now explicitly engages the PCAC outcome (see Peer-Reviewed Analysis below), and gray-market migration to 503A compounding pharmacies continues to accelerate.
06Critical Timeline
- 2023: Category 2 restrictions on >12 peptides (safety concerns: immunogenicity, impurities, limited human data)
- 2024–2025: Warning letter wave; Sept 2025: 50+ letters
- Late 2025: DOJ criminal pleas
- March 6, 2026: Peptide Sciences shutdown
- April 15-16, 2026: FDA Federal Register notice (FR Doc. 2026-07361); removal from Category 2; PCAC July 23-24, 2026 announced
- July 23-24, 2026: PCAC VOTE COMPLETE — committee recommended 6 of 7 for the 503A Bulks List: BPC-157 (8–6), KPV (8–6), TB-500 ✓, MOTS-c ✓, Epitalon (7–5), Semax (8–5); Emideltide/DSIP rejected (6–7). All votes went against FDA career-staff recommendations. FDA final decision pending. See FDA peptide reclassification 2026
- July-August 2026 (post-PCAC): Peer-reviewed pharmacy-compounding analysis of the PCAC vote published in Int J Pharm Compd (Willis & Vu, PMID 42752426) — first non-regulatory, non-industry professional assessment of the July recommendations and the industry safety-standards gap
- September 2026: BPC-157 ischemia-reperfusion critical review published (Demirtaş, PMID 42794771) — pre-clinical evidence synthesis that FDA career staff did not have when briefing the committee
- February 2027 (planned): Follow-up PCAC for additional 5 peptides (GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF)
07July 23-24, 2026 PCAC Agenda (Primary Source: FDA.gov)
July 23, 2026 (BPC-157, KPV, TB-500, MOTS-c): - BPC-157 (free base/acetate): Ulcerative colitis - KPV (free base/acetate): Wound healing and inflammatory conditions - TB-500 (free base/acetate): Wound healing - MOTS-c (free base/acetate): Obesity and osteoporosis
July 24, 2026 (Emideltide/DSIP, Semax, Epitalon): - Emideltide (DSIP, free base/acetate): Opioid withdrawal, chronic insomnia, narcolepsy - Semax (free base/acetate): Cerebral ischemia, migraine, trigeminal neuralgia - Epitalon (free base/acetate): Insomnia
Note: FDA has posted briefing documents for all seven. PCAC recommendations are non-binding; addition to 503A Bulks List requires formal notice-and-comment rulemaking (typically >1 year). A follow-up PCAC is scheduled before end of February 2027 for five additional peptides.
08Open questions
- Will FDA accept all 6 recommended peptides, or split the decision (e.g., accept the wound-healing ones — KPV, TB-500, BPC-157 — and defer Epitalon, Semax, MOTS-c pending characterization data)?
- What is the timeline for final rule? Notice-and-comment rulemaking has historically taken 12-18 months even on uncontested nominations.
- Will FDA require a USP monograph before listing, given Willis & Vu's safety-standards analysis?
- What will legal access cost? Anecdotal reports (Q3 2026) suggest 30–50% price increases on telehealth peptide consultations to cover pharmacy-grade supply.
- Will the February 2027 PCAC tranche (GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF) follow the same pattern? All five have similar evidence-base profiles to the July cohort.
09Connections
10Sources
- PubMed PMID 42752426 — Willis & Vu, Int J Pharm Compd (peer-reviewed PCAC analysis)PubMed 42752426
- PubMed PMID 42794771 — Demirtaş, Int J Mol Sci (BPC-157 ischemia-reperfusion review)PubMed 42794771
- PubMed PMID 42542926 — Biçer et al., Jt Dis Relat Surg (BPC-157 + TB-500 Achilles tendon)PubMed 42542926
11Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.